#pcsk9 inhibitor

Evolocumab: A Game Changer in Preventing First Heart Attacks and Strokes with a 31% Risk Reduction

A groundbreaking new study reveals that the innovative cholesterol-lowering drug Evolocumab can slash the risk of first-time heart attacks and strokes by an impressive 31% in high-risk individuals. This finding heralds a new era in primary cardiovascular disease prevention, offering profound hope and a powerful new tool in the fight against these devastating conditions.